Company intelligence / Profile preview

Blue Oak Pharmacy

Waltham, Massachusetts, United Stateske.linkedin.com ↗

Ownership: Private
Employees: ~9
Development stage: Other

Overview

Blue Oak Pharmaceuticals develops first-in-class small molecule therapeutics targeting behavioral symptoms associated with mental illnesses such as schizophrenia, bipolar disorder, geriatric psychosis, and treatment-resistant depression. The company uses proprietary chemotype libraries combined with advanced phenotypic screening platforms—including AI/machine learning partnerships—to identify novel mechanisms of action. All known internal programs remain at preclinical stage as of mid–2025.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

PsychoGenicsExscientia

Beyond the preview

Go deeper on Blue Oak Pharmacy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blue Oak Pharmacy.

Explore the full profile